Who Paid My Doc
Alyssa Letourneau
Infectious Disease Boston, MA Medical Doctor
NPI 1225164635 CMS profile 483728
Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114
General payments
$0
Research payments
$60
Ownership & investment interest
$0
Through program year 2019, Alyssa Letourneau of Boston, MA is reported in the CMS Open Payments database as having received $0 across 0 general payments and $60 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 17th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | Research | $60 | 1 |
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
175
Drug cost
$20,771
Branded share of claims
14.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Posaconazole | Generic | 20 | $17,042 | |
| Ethambutol Hcl | Generic | 19 | $946 | |
| Rifampin | Generic | 19 | $766 | |
| Azithromycin | Generic | 29 | $714 | |
| Doxycycline Monohydrate | Generic | 16 | $622 | |
| Amoxicillin | Generic | 28 | $267 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 11 | $157 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 14 | $141 | |
| Cefadroxil | Generic | 19 | $116 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$37,468
Medicare patients
149
Services billed
392
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| COPD | 46% | |
| Arthritis | 46% | |
| Chronic kidney disease | 38% | |
| Ischemic heart disease | 37% | |
| Depression | 34% | |
| Atrial fibrillation | 32% | |
| Diabetes | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Massachusetts
Related records
Infectious Disease in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.